Starget After the Round: Funding Bought Time, the Going-Concern Warning Still Sets the Pace
The Series A round and SAFE conversion improved Starget's cash position and increased Ilex's stake, but they did not remove the central risk. Starget still has no revenue, is burning cash, and the next financing extension is part of the thesis, not a footnote.
Starget is no longer a side note for Ilex Medical. The Series A round in early 2026, the SAFE conversion and the increase to a 39.64% stake turned it into a NIS 55.4 million equity-method investment and into a factor that now draws both losses and management attention. But the new funding did not change the nature of the risk: Starget still has no revenue, used NIS 6.2 million in operating cash during the quarter, and its financial statements include an emphasis of matter over substantial doubt about its ability to continue as a going concern. That does not mean the investment has failed. It means the capital raised bought time until clinical milestones and additional funding, not business proof. The path forward now depends on starting the first-in-human trial and completing the Series A extension of up to $5 million, or securing another clear funding source. Ilex owns a larger clinical option than before, but it is also more exposed to the cash burn of a company that still has to prove it can finance the next stage.
The Round Made Starget More Material, Not More Mature
The financing move in the first quarter did two things at once. It improved Starget's balance sheet, and it increased Starget's weight inside Ilex. During the quarter, Ilex invested another $3 million, about NIS 9.5 million, and the overall round reached $18.2 million. After the investment and SAFE conversion, Ilex's holding rose to 39.64% of Starget's share capital, or 32.75% on a fully diluted basis.
The important number at Ilex is not only the ownership percentage. The equity-method investment rose to NIS 55.4 million at the end of March 2026 from NIS 25.1 million at the end of 2025. Starget is now large enough on the balance sheet to affect Ilex's capital-allocation quality, even though it still generates no revenue.
Still, a cleaner capital structure is not the same as business maturity. Starget raised NIS 24.97 million in net cash through Series A and converted a NIS 39.85 million SAFE liability into preferred shares. That moved shareholders' equity from a NIS 32.0 million deficit at the end of 2025 to positive equity of NIS 25.9 million at the end of March. This is a sharp balance-sheet improvement, but mainly a financing and capital-structure change. It does not change the fact that the product remains before first human clinical proof.
Starget's Numbers Still Speak the Language of Funding
The cash frame here is all-in cash flexibility: not only how much money entered the company, but what remains after operating burn, investments, leases and financing cash uses. On that basis, the quarter explains why the going-concern emphasis stayed central even after the round.
| Starget item | What changed in the quarter | What remains unresolved |
|---|---|---|
| Cash and cash equivalents | Rose to NIS 25.8 million | Operating cash flow was negative NIS 6.2 million |
| Equity | Moved to positive equity of NIS 25.9 million | Accumulated losses reached NIS 91.4 million |
| SAFE | NIS 39.85 million liability converted into preferred shares | Preferred shareholders received senior distribution and liquidation rights |
| Clinical trial | Agreement exists with an Australian CRO for a first-in-human imaging trial | The trial had not started by quarter-end |
| Additional funding | Board approved a May Series A extension of up to $5 million | Approval is not the same as cash already received |
The table shows the gap between "there is cash" and "there is a funded path to proof." Starget ended the quarter with NIS 25.8 million in cash, but its activity consumed NIS 6.2 million in three months and management expects substantial operating losses to continue until product development is completed and marketing approvals are obtained. Even without assuming the burn rate remains unchanged, the company itself ties its continuity to raising funds from current and outside investors, with no assurance that funding will be available or secured on favorable terms.
This is the less comfortable side of financing rounds in an early-stage life-sciences company. The SAFE conversion removes a large accounting liability and improves equity, but it also creates a preferred-rights layer ahead of common shareholders in distributions or liquidation. For Ilex, the investment looks larger and more structured, yet its value still runs through the same practical question: whether Starget can turn the time it bought into clinical progress that supports the next financing round on reasonable terms.
The Round Extension Is the Next Milestone, Not a Footnote
The post-period event matters because it reveals the real pace of the story. On May 17, 2026, Starget's board approved an additional financing of up to $5 million through the sale of Series A shares at the same price of $17.3562 per share, during the 120-day period following the initial closing. If the February round had been an endpoint, this extension would not carry the same weight so soon after the quarter.
The first-in-human trial is the business proof point. Starget signed a Master Agreement in February 2025 with an Australian CRO for a first-in-human imaging trial of a novel cyclic peptide radioligand, but the trial had not started by quarter-end. As long as the trial has not begun, the new capital improves the probability of reaching that milestone, but does not prove that the company has moved from funding to clinical validation.
That is also why the going-concern emphasis is not just an accounting caveat. It describes the risk structure: no revenue, accumulated losses, cash burn and dependence on additional equity raises. There is also a clear positive point: after the round, Starget is not entering the next stage with negative equity and a short-term SAFE burden weighing on the balance sheet. It received time. Now it has to turn that time into clinical data, or into additional funding that shows investors are still willing to pay for the risk.
What Has to Be Proven Now
Starget gives Ilex a different kind of potential than the regular distribution business: not inventory, customers and currency, but a clinical path where value can change sharply around a trial, regulation and funding. The first quarter strengthened that potential on the balance sheet, but also made the bottleneck more visible. As long as the going-concern warning remains, the first trial has not started, and the round extension still has to become actual cash, Starget is a material holding with more time, not a mature business asset. The turning point would be a combination of trial initiation, a cash-burn pace that stays under control, and follow-on funding that does not signal pressure on terms.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.